Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Early sunburn treatment with certain inhibitors may reduce skin cancer risk.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

New vitamin D3 forms need the vitamin D receptor to reduce fibrosis in human cells.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

The inhibitor affects androgen metabolism but not ovarian function.

Dexamethasone reduces inflammation and delays skin cell changes caused by TPA.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

Doxazosin may cause breast enlargement and pain in men.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

OR-101 shows promise for treating alopecia areata by improving hair growth.

Using DNase enzymes to break down harmful NETs could be a new treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

Inhibiting ODC can prevent UV-induced skin cancer.

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

Topical tacalcitol ointment can help improve symptoms of EFFC.

Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.

Tofacitinib helped a man with alopecia totalis regrow all his hair.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.